Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

121. Decisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosis

Decisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosis Decisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosis Decisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosis Butler M, Forte ML, Schwehr N, Carpenter A, Kane RL Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Butler M, Forte ML, Schwehr N, Carpenter A, Kane RL. Decisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosis. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 150. 2015 Authors' objectives We conducted a systematic review to examine the long-term consequences of discontinuing disease-modifying treatment (DMT) for multiple sclerosis (MS) by examining the long

Health Technology Assessment (HTA) Database.2015

123. Telerehabilitation for persons with multiple sclerosis.

Telerehabilitation for persons with multiple sclerosis. BACKGROUND: Telerehabilitation, an emerging method, extends rehabilitative care beyond the hospital, and facilitates multifaceted, often psychotherapeutic approaches to modern management of patients using telecommunication technology at home or in the community. Although a wide range of telerehabilitation interventions are trialed in persons with multiple sclerosis (pwMS), evidence for their effectiveness is unclear. OBJECTIVES (...) the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Review Group Specialised Register( 9 July, 2014.) We handsearched the relevant journals and screened the reference lists of identified studies, and contacted authors for additional data. SELECTION CRITERIA: Randomised controlled trials (RCTs) and controlled clinical trials (CCTs) that reported telerehabilitation intervention/s in pwMS and compared them with some form of control intervention (such as lower level or different

Cochrane2015

125. Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial

Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial 25795646 2015 04 14 2015 06 15 2016 12 15 1526-632X 84 15 2015 Apr 14 Neurology Neurology Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. 1582-91 10.1212/WNL.0000000000001462 To assess long-term safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS). Patients completing FTY720 Research Evaluating Effects of Daily (...) Oral Therapy in MS (FREEDOMS) were eligible for this dose-blinded, parallel-group extension study, continuing fingolimod 0.5 mg/day or 1.25 mg/day, or switching from placebo to either dose, randomized 1:1. Efficacy variables included annualized relapse rate (ARR), brain volume loss (BVL), and confirmed disability progression (CDP). Between-group analyses were conducted in the intent-to-treat (ITT) population from FREEDOMS baseline to end of study. Within-group analyses compared years 0-2 (FREEDOMS

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

126. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis

The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis The Cannabinoid Use (...) in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis Ball S, Vickery J, Hobart J, Wright D, Green C, Shearer J, Nunn A, Cano MG, MacManus D, Miller D, Mallik S, Zajicek J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made

Health Technology Assessment (HTA) Database.2015

127. Multiple sclerosis: neither natalizumab nor alemtuzumab

Multiple sclerosis: neither natalizumab nor alemtuzumab Prescrire IN ENGLISH - Spotlight ''Multiple sclerosis: neither natalizumab nor alemtuzumab'', 1 March 2015 {1} {1} {1} | | > > > Multiple sclerosis: neither natalizumab nor alemtuzumab Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Multiple sclerosis: neither natalizumab nor alemtuzumab (...) With the benefit of hindsight, natalizumab (Tysabri°) has proved even more toxic than expected in multiple sclerosis patients. Evaluation of alemtuzumab (Lemtrada°) is too biased for its potential usefulness to be judged, however it exposes patients to severe adverse effects. The reference treatment for relapsing-remitting multiple sclerosis which progresses in flare-ups is interferon beta injection, for lack of anything better. In 2007, in severe multiple sclerosis when interferon beta does not seem

Prescrire2015

128. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system.

Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. IMPORTANCE: Case reports have suggested a link between human papillomavirus (HPV) vaccination and development of multiple sclerosis and other demyelinating diseases. OBJECTIVE: To investigate if quadrivalent HPV (qHPV) vaccination is associated with an increased risk of multiple sclerosis and other demyelinating diseases. DESIGN, SETTING, AND PARTICIPANTS: Using nationwide (...) registers we identified a cohort of all females aged 10 years to 44 years in Denmark and Sweden, followed up from 2006 to 2013, information on qHPV vaccination, and data on incident diagnoses of multiple sclerosis and other demyelinating diseases. The primary analysis used a cohort design including vaccinated and unvaccinated study participants. A secondary analysis used a self-controlled case-series design including only cases. Both analyses used a 2-year risk period following vaccination. EXPOSURES

JAMA2015 Full Text: Link to full Text with Trip Pro

130. Cohort study: The human papillomavirus vaccination is not associated with risk of multiple sclerosis or other demyelinating diseases

Cohort study: The human papillomavirus vaccination is not associated with risk of multiple sclerosis or other demyelinating diseases The human papillomavirus vaccination is not associated with risk of multiple sclerosis or other demyelinating diseases | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The human papillomavirus vaccination is not associated with risk of multiple sclerosis or other demyelinating diseases Article Text Aetiology/Harm Cohort study The human papillomavirus vaccination is not associated with risk of multiple sclerosis

Evidence-Based Medicine (Requires free registration)2015

131. Biotin (Cerenday) for primary and secondary progressive multiple sclerosis - first line

Biotin (Cerenday) for primary and secondary progressive multiple sclerosis - first line Biotin (Cerenday) for primary and secondary progressive multiple sclerosis - first line Biotin (Cerenday) for primary and secondary progressive multiple sclerosis - first line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Biotin (Cerenday) for primary (...) and secondary progressive multiple sclerosis - first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Cerenday (biotin) is a high dose oral formulation of biotin, a water soluble vitamin that acts as a coenzyme for carboxylases involved in key steps of energy metabolism and fatty acid synthesis. Very high doses of biotin may be efficacious in multiple sclerosis (MS) by promoting myelin repair through activation of acetyl-CoA carboxylase

Health Technology Assessment (HTA) Database.2015

132. Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses - add on therapy to current immunomodulators

Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses - add on therapy to current immunomodulators Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Cerenday (biotin) is a high dose oral formulation of biotin, a water soluble vitamin that acts as a coenzyme for carboxylases involved in key steps of energy metabolism and fatty

Health Technology Assessment (HTA) Database.2015

133. Natalizumab (Tysabri) for secondary progressive multiple sclerosis

Natalizumab (Tysabri) for secondary progressive multiple sclerosis Natalizumab (Tysabri) for secondary progressive multiple sclerosis Natalizumab (Tysabri) for secondary progressive multiple sclerosis NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Natalizumab (Tysabri) for secondary progressive multiple sclerosis. Birmingham: NIHR Horizon (...) Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Natalizumab (Tysabri) is intended for the treatment of secondary progressive multiple sclerosis (SPMS) in patients who have progressed from relapsing remitting MS. If licensed, natalizumab will offer an additional treatment option for patients with SPMS, a group who currently have few effective therapies available. No disease-modifying drugs are currently licensed specifically for SPMS. Natalizumab is a selective

Health Technology Assessment (HTA) Database.2015

134. Masitinib for primary and relapse-free secondary progressive multiple sclerosis - first line

Masitinib for primary and relapse-free secondary progressive multiple sclerosis - first line Masitinib for primary and relapse-free secondary progressive multiple sclerosis – first line Masitinib for primary and relapse-free secondary progressive multiple sclerosis – first line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Masitinib (...) for primary and relapse-free secondary progressive multiple sclerosis – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Masitinib is intended to be used as first line therapy for the treatment of primary progressive or relapse-free secondary progressive multiple sclerosis. If licensed, masitinib will offer a novel, oral treatment option for this patient group for whom no licensed therapies are currently available. Masitinib

Health Technology Assessment (HTA) Database.2015

135. Identification and Management of Depression in Multiple Sclerosis

Identification and Management of Depression in Multiple Sclerosis IDENTIFICATION AND MANAGEMENT OF DEPRESSION IN MULTIPLE SCLEROSIS Clinical Practice Guideline | December 2015 These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. They should be used as an adjunct to sound clinical decision making. OBJECTIVE Alberta clinicians have the skills and tools to assess, diagnose (...) , treat and manage depression in patients with multiple sclerosis (MS) within primary care. TARGET POPULATION Adults 18 years of age and older EXCLUSIONS Children less than 18 years of age RECOMMENDATIONS PRACTICE POINT Be aware that depression is two to three times more common in MS patients than in the general population and can go undetected. Be aware that the suicide rate in people with MS is approximately twice that of the general population. Therefore it is important to be vigilant

Toward Optimized Practice2015

136. Randomised controlled trial: Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosi

Randomised controlled trial: Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosi Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosis | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosis Article Text Therapeutics/Prevention Randomised controlled trial Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosis Free Gareth Pryce , David Baker Statistics from

Evidence-Based Medicine (Requires free registration)2015

137. Multiple sclerosis

Multiple sclerosis Multiple sclerosis - NICE CKS Clinical Knowledge Summaries Share Multiple sclerosis - Summary Multiple sclerosis (MS) is a presumed autoimmune inflammatory condition of the central nervous system (CNS) resulting in areas of demyelination (damage to white matter), gliosis (subsequent scarring), and secondary neuronal damage (cell loss) throughout the CNS. Typically, MS first develops in young adults and is the most common non-traumatic cause of significant neurological (...) disability in people younger than 40 years. There are three main patterns of the disease: Relapsing–remitting MS (RRMS) — episodes of symptoms (relapses) are followed by recovery (remissions) and periods of stability. Typically, after several relapses there remains residual damage to parts of the CNS which results in only a partial recovery during remissions. About 85% of people with MS have RRMS at onset. Secondary progressive MS (SPMS) — the onset is of the RRMS pattern. But, at some point later

NICE Clinical Knowledge Summaries2015

138. Rehabilitation in multiple sclerosis

Rehabilitation in multiple sclerosis Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis | Neurology Advertisement Search for this keyword Main menu User menu Search Search for this keyword The most widely read and highly cited peer-reviewed neurology journal Share November 24, 2015 ; 85 (21) Special Article Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis Report of the Guideline Development, Dissemination, and Implementation (...) Getchius Gary Gronseth Melissa J. Armstrong Pushpa Narayanaswami Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis Jodie K. Haselkorn , Christina Hughes , Alex Rae-Grant , Lily Jung Henson , Christopher T. Bever , Albert C. Lo , Theodore R. Brown , George H. Kraft , Thomas Getchius , Gary Gronseth , Melissa J. Armstrong , Pushpa Narayanaswami Neurology Nov 2015, 85 (21) 1896-1903; DOI: 10.1212/WNL.0000000000002146 Citation Manager Formats Downloads 4197 Share Abstract

American Academy of Neurology2015

139. Dimethyl fumarate (multiple sclerosis ? relapsing-remitting) ? Benefit assessment according to §35a Social Code Book V

Dimethyl fumarate (multiple sclerosis ? relapsing-remitting) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dimethylfumarat – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 July 2014). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A14 (...) ? Sarah Mostardt ? Katrin Nink ? Sibylle Sturtz ? Beate Wieseler ? Min Zhou Keywords: dimethyl fumarate, multiple sclerosis – relapsing-remitting, benefit assessment 2 Due to legal data protection regulations, employees have the right not to be named. Extract of dossier assessment A14-14 Version 1.0 Dimethyl fumarate – Benefit assessment acc. to §35a Social Code Book V 30 July 2014 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List

Institute for Quality and Efficiency in Healthcare (IQWiG)2014

140. Daclizumab High Yield Process for relapsing forms of multiple sclerosis ? first or second line

Daclizumab High Yield Process for relapsing forms of multiple sclerosis ? first or second line Daclizumab High Yield Process for relapsing forms of multiple sclerosis – first or second line Daclizumab High Yield Process for relapsing forms of multiple sclerosis – first or second line NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation NIHR HSC. Daclizumab High Yield Process for relapsing forms of multiple sclerosis – first or second line. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanizeds; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting Language Published English Country of organisation England English summary An English language summary is available. Address

Health Technology Assessment (HTA) Database.2014